Efficacy and safety of fluticasone propionate 44 μg/salmeterol 21 μg administered in a hydrofluoroalkane metered-dose inhaler as an initial asthma maintenance treatment

Annals of Allergy, Asthma and Immunology

Volumn 91, Issue 3, 2003, Pages 263-269

  Nelson, Harold S ^a   Wolfe, James D ^b   Gross, Gary ^c   Greos, Leon S ^d   Baitinger, Leslie ^e   Scott, Catherine ^e   Dorinsky, Paul ^e  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b Allergy & Asthma Associates of Northern California   (United States)

^c Pharmaceutical Research and Consulting Inc   (United States)

^d Clin Research Centers of Colorado   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHLOROFLUOROCARBON; CORTICOSTEROID; FLUORINATED HYDROCARBON; FLUTICASONE PROPIONATE; SALBUTAMOL; SALMETEROL; SALMETEROL XINAFOATE;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; CANDIDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPHONIA; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HOARSENESS; HUMAN; MAINTENANCE THERAPY; MALE; METERED DOSE INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROAT DISEASE;

EID: 0141656344     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)63528-4     Document Type: Article

References (19)

1. National Institutes of Health. National Heart, Lung, and Blood Institute. Highlights of the Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Institutes of Health; 1997. Publication 97-4051A:1-50.
2. Condemi JJ, Goldstein S, Kalberg C, Yancey S, Emmett A, Rickard K. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group. Ann Allergy Asthma Immunol. 1999;82:383-389.
3. Greening A, Ind P, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroids. Lancet. 1994;344:219-224.
4. Murray JJ, Church NL, Anderson WH, et al. Concurrent use of salmeterol with inhaled corticosteroids is more effective than inhaled corticosteroid dose increases. Allergy Asthma Proc. 1999;20:173-180.
5. Pearlman DS, Stricker W, Weinstein S, et al. Inhaled salmeterol and fluticasone propionate: a study comparing monotherapy and combination therapy in asthma. Ann Allergy Asthma Immunol. 1999;82:257-265.
6. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased doses of inhaled steroids or addition of salmeterol in symptomatic asthma (MIASMA). BMJ. 2000;320:1368-1373.
7. Van Noord JA, Schreurs AJ, Mol SJ, Mulder PG. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax. 1999;54:207-212.
8. Vermetten FA, Boermans AJ, Luiten WD, Mulder PG, Vermue NA. Comparison of salmeterol with beclomethasone in adult patients with mild persistent asthma who are already on low-dose inhaled steroids. J Asthma. 1999;36:97-106.
9. Woolcock A, Lundback B, Ringdal N, Jacques L. Comparison of addition of salmeterol to inhaled steroids with doubling the dose of inhaled steroids. Am J Respir Crit Care Med. 1996;153:1481-1488.
10. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. American Thoracic Society. Am J Respir Crit Care Med. 1995;152: S77-S121.
11. European Community for Coal and Steel. Report of the Working Party of the European Community for Coal and Steel. Standardization of lung function tests. Eur Respir J. 1993;16:1-100.
12. Polgar G, Promadhat V. Pulmonary Function Testing in Children: Techniques and Standards. Philadelphia, PA: WB Saunders; 1971:1-269.
13. Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society. Am Rev Respir Dis 1991;144:1202-1218.
14. Shapiro G, Lumry W, Wolfe J, et al. Combined salmeterol 50 μg and fluticasone propionate 250 μg in the Diskus device for the treatment of asthma. Am J Respir Crit Care Med. 2000;161:527-534.
15. Kavuru M, Melamed J, Gross G, et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2000;105:1108-1116.
16. Neuhauser M, Steinijans VW, Bretz F. The evaluation of multiple clinical endpoints, with application to asthma. Drug Inf J. 1999;33:471-477.
17. 2-agonists alone. Am J Respir Crit Care Med. 2001;164:759-763.
18. Pearlman DS, White MV, Lieberman AK, et al. Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma. Ann Allergy Asthma Immunol. 2002;88:227-235.
19. Schulman, Ronca, and Bucuvalas, Inc (SRBI). Asthma in America: A Landmark Survey. New York, NY: SRBI; 1998.